Patent US4244052A successfully refreshed from Google Patents.
Patent US6017735A successfully refreshed from Google Patents.
US6017735A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Materials and methods for intracellular transport and their uses
Assignee: Marie Curie Cancer Care
•
Filing: 1998-01-22
•
Granted: 2000-01-25
•
Expires: 2018-01-22
Abstract
Abstract Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.
Inventors
- 👤 Peter Francis Joseph O'Hare
- 👤 Gillian Daphne Elliott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 12:43
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61P; A61P37/00; A61P37/02; A61P37/04; C07K2319/00; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16611; C12N2710/16622; Y; Y10; Y10S; Y10S530/00; Y10S530/82; Y10S530/826
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
77 words
A fusion polypeptide comprising first and second amino acid sequences, wherein the first amino acid sequence comprises a herpesvirus VP22 protein or a fragment thereof that retains a herpesvirus VP22 protein transport function and the second amino acid sequence comprises a protein selected from the group consisting of: (a) proteins for cell cycle control; (b) suicide proteins; (c) immunomodulating proteins; (d) therapeutic proteins; and (e) fragments of (a)-(d) that retain one or more functions of that protein.
Claim 2
Dependent Claim
77 words
A fusion polypeptide comprising first and second amino acid sequences, wherein the first amino acid sequence comprises a herpesvirus VP22 protein or a fragment thereof that retains a herpesvirus VP22 protein transport function and the second amino acid sequence comprises a protein selected from the group consisting of: (a) proteins for cell cycle control; (b) suicide proteins; (c) immunomodulating proteins; (d) therapeutic proteins; and (e) fragments of (a)-(d) that retain one or more functions of that protein.
Claim 3
Dependent Claim
19 words
A polypeptide according to claim 1 wherein the second amino acid sequence is a mammalian cell cycle control protein.
Claim 4
Dependent Claim
33 words
A polypeptide according to claim 2 wherein the second amino acid sequence is a mammalian protein for increasing or inducing cell apoptosis or for conferring on a cell the ability to undergo apoptosis.
Claim 5
Dependent Claim
39 words
A polypeptide according to claim 2 wherein the second amino acid sequence is a mammalian cell cycle control protein selected from the group consisting of p53 proteins, cyclin dependent kinase inhibitors, and proteins of the bcl2 and bax families.
Claim 6
Dependent Claim
16 words
A polypeptide according to claim 4 wherein the second amino acid sequence comprises a p53 protein.
Claim 7
Dependent Claim
30 words
A polypeptide according to claim 5, wherein the first amino acid sequence is a full length VP22 sequence and the second amino acid sequence is a full length p53 sequence.
Claim 8
Dependent Claim
16 words
A polypeptide according to claim 1 wherein the second amino acid sequence is a suicide protein.
Claim 9
Dependent Claim
17 words
A polypeptide according to claim 7 wherein said suicide protein is selected from thymidine kinase and nitroreductase.
Claim 10
Dependent Claim
18 words
A polypeptide according to claim 7, wherein the first amino acid sequence is a full length VP22 sequence.
Claim 11
Dependent Claim
21 words
A polypeptide according to claim 1, wherein the first and second amino acid sequences are joined by a cleavage-inducing linker sequence.
Claim 12
Dependent Claim
29 words
A polypeptide according to claim 1, wherein the fragment of the herpesvirus VP22 comprises from about amino acid 159 to about amino acid 301 of the HSV VP22 protein.
Claim 13
Dependent Claim
52 words
A polypeptide according to claim 1, wherein the fragment of the herpesvirus VP22 comprises a sequence selected from the group consisting of (a) from about amino acid 60 to about amino acid 301 and (b) from about amino acid 159 to about amino acid 301 of the full length HSV VP22 sequence.
Claim 14
Dependent Claim
9 words
A polynucleotide encoding a polypeptide according to claim 1.
Claim 15
Dependent Claim
9 words
A vector comprising a polynucleotide according to claim 13.
Claim 16
Dependent Claim
10 words
A host cell comprising a vector according to claim 14.
Claim 17
Independent Claim
46 words
A method of transporting a first polypeptide into a cell population, comprising exposing the cells to a fusion polypeptide comprising (a) the first polypeptide; and (b) a second polypeptide comprising a herpesvirus VP22 protein or a fragment thereof that retains a herpesvirus VP22 protein transport function.
Claim 18
Independent Claim
46 words
A method of transporting a first polypeptide into a cell population, comprising exposing the cells to a fusion polypeptide comprising (a) the first polypeptide; and (b) a second polypeptide comprising a herpesvirus VP22 protein or a fragment thereof that retains a herpesvirus VP22 protein transport function.
Claim 19
Dependent Claim
45 words
The method of claim 16 wherein the first polypeptide is selected from the group consisting of (a) proteins for cell cycle control; (b) suicide proteins; (c) immunomodulating proteins; (d) therapeutic proteins; and (e) fragments of (a)-(d) that retain one or more functions of that protein.
Claim 20
Dependent Claim
28 words
The polypeptide of claim 1 wherein the first amino acid sequence comprises a HSV VP22 protein or a fragment thereof that retains a HSV VP22 protein transport function.
Claim 21
Dependent Claim
26 words
The method of claim 16 wherein the second polypeptide comprises a HSV VP22 protein or a fragment thereof that retains a HSV VP22 protein transport function.
References Cited (Backward Citations)
EP0475623A1
Cited
WO1997004092A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-01-24 | 2003-07-26 | 2004-01-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-01-24 | 2007-07-26 | 2008-01-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-01-24 | 2011-07-26 | 2012-01-25 | $7700.00 | Window Closed / Lapsed |